Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B. Corcoran, Geoffrey I. Shapiro, Niya Xiong et al.|Clinical Cancer Research|2024Cited by 39
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F. Liu, Ursula A. Matulonis, Niya Xiong et al.|Gynecologic Oncology|2024Cited by 11
Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trialAndrew B. Nixon, Angeles Alvarez Secord, Joyce F. Liu et al.|Gynecologic Oncology|2021Cited by 1